Fluid Biomarker Core

FBM核心摘要/摘要 阿尔茨海默病（AD）病理生理学超灵敏血液生物标志物检测的最新进展 表明血浆生物标志物可以彻底改变AD研究和临床实践。流体生物标志物和 方法（FBM）核心是在PPG 4中创建的，以响应这些进步，并将负责 协调血液采集、预分析程序、库存、分析和持续供应血液 生物标志物的价值。FBM核心将为所有项目产生结果，并将与 所有其他核心我们将以易于使用的格式提供血液生物标志物的质量控制结果 与其目标相关的分析。与神经影像学和 神经病理学团队，我们将有助于验证先前开发的血浆生物标志物测定， FBM核心团队成员和其他团体反对经过更好验证的神经成像和尸检结果。 FBM核心将寻求与AD及相关领域的几项大型多中心研究合作， 使用大数据方法推进血液生物标志物的知识。我们将每月举行一次 与其他PPG研究人员开会，讨论血液采集和分析，并讨论 血液生物标志物的方法学和科学方面。FBM核心还将为学生提供培训， 博士后，以及流体生物标志物方法和分析的教师。需要强调的是， 神经成像生物标志物技术在以前的PPG周期已经把FBM核心在一个特权 能够使用这些最先进的神经影像学结果来支持使用新血液获得的措施 生物标志物测定。FBM核心的具体目标是：（目标1）协调收集，预分析 PPG中血浆生物标志物的程序、储存和分析4。(Aim（2）提供优质服务- 控制Aβ、tau、神经变性和神经炎症的血浆生物标志物值，以支持目标 在项目1-4中详细描述。(Aim 3）与成像生物标志物方法核心合作，我们 旨在验证血浆生物标志物测定对神经影像学结果的影响。(Aim（4）与 神经病理学团队（项目4），我们的目标是验证血浆生物标志物测定对死后病理学 结果。(Aim 5）对学生、博士后研究员和教师进行血浆生物标志物方法的培训。在 在本研究中，我们将生成第一个包含血液和神经影像测量的大规模纵向数据集 星形胶质细胞增生、Aβ、tau蛋白和神经变性。这些项目利用下列机构提供的数据产生的结果： FBM核心将有助于阐明AD中多种病理之间的复杂相互作用。验证 血液生物标志物测量与更好的神经成像和死后结果的对比将 指出了使用这些血浆生物标志物来鉴定AD中的脑病理的优点和注意事项。

FBM Core Summary/Abstract Recent advances in ultrasensitive blood biomarker assays for Alzheimer’s disease (AD) pathophysiology suggest that plasma biomarkers can revolutionize AD research and clinical practice. The Fluid Biomarker and Methodology (FBM) Core was created in PPG4 in response to these advances and will be responsible for coordinating blood collections, pre-analytical procedures, banking, analysis, and supplying continuous blood biomarker values to the projects. The FBM Core will generate results for all projects and will be integrated with all other cores. We will provide quality-controlled results of blood biomarkers in a format that can be easily used by projects for the analyzes associated with their aims. In collaboration with the neuroimaging and neuropathology teams, we will contribute to the validation of plasma biomarker assays previously developed by FBM Core team members and other groups against better-validated neuroimaging and postmortem outcomes. The FBM Core will seek to collaborate with several large-scale multi-site studies in the field of AD and related dementia to advance the knowledge of blood biomarkers using a big data approach. We will hold monthly meetings with other PPG researchers to discuss blood collection and analysis, as well as to discuss methodological and scientific aspects of blood biomarkers. The FBM Core will also provide training for students, postdocs, and faculty in fluid biomarker methods and analyses. It is important to emphasize that the optimization of neuroimaging biomarker techniques in the previous PPG cycles has placed the FBM Core in a privileged position to use these state-of-art neuroimaging outcomes to support the measures obtained with the new blood biomarker assays. The specific aims of the FBM Core are: (Aim 1) To coordinate the collection, pre-analytical procedures, storage, and analysis of blood plasma biomarkers across the PPG4. (Aim 2) To provide quality- controlled plasma biomarker values of Aβ, tau, neurodegeneration, and neuroinflammation in support of the aims described in detail in Projects 1-4. (Aim 3) In collaboration with the Imaging Biomarkers Methodology Core, we aim to validate plasma biomarker assays against neuroimaging outcomes. (Aim 4) In collaboration with the neuropathology team (Project 4), we aim to validate plasma biomarker assays against postmortem pathological outcomes. (Aim 5) To train students, post-doctoral fellows, and faculty in plasma biomarker methods. In the present study, we will generate the first large-scale longitudinal dataset with blood and neuroimaging measures of astrogliosis, Aβ, tau, and neurodegeneration. The results generated by the projects with the data provided by the FBM Core will help to elucidate the complex interactions between multiple pathologies in AD. The validation of blood biomarker measurements against better-established neuroimaging and postmortem outcomes will indicate the advantages and caveats of using these plasma biomarkers to identify brain pathologies in AD.